


d[Cha4]-AVP

Cat. No.:	HY-P1390
CAS No.:	500170-27-4
Molecular Formula:	C ₉₀ H ₇₁ N ₁₃ O ₁₁ S ₂
Molecular Weight:	1094.31
Sequence:	{Mpa}-Tyr-Phe-{Cha}-Asn-Cys-Pro-Arg-Gly-NH ₂ (Disulfide bridge:Mpa1-Cys6)
Sequence Shortening:	{Mpa}-YF-{Cha}-NCPRG-NH ₂ (Disulfide bridge: Mpa1-Cys6)
Target:	Vasopressin Receptor
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (91.38 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM	0.9138 mL	4.5691 mL	9.1382 mL	
		5 mM	0.1828 mL	0.9138 mL	1.8276 mL	
		10 mM	0.0914 mL	0.4569 mL	0.9138 mL	
Please refer to the solubility information to select the appropriate solvent.						

BIOLOGICAL ACTIVITY

Description	d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a K _i of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors ^{[1][2]} .
IC ₅₀ & Target	Ki: 1.2 nM (vasopressin V1B receptor), 151 nM (vasopressin V1A receptor), 240 nM (Oxytocin receptor), 750 nM (vasopressin V2 receptor) ^[1]
In Vitro	d[Cha4]-AVP binds to hV1b receptors and human oxytocin receptors with pK _i values of 9.68 and 7.68, respectively ^[2] . d[Cha4]-AVP stimulates [Ca ²⁺] _i increase in hV1b-CHO cells with a pEC ₅₀ value of 10.05. d[Cha4]-AVP shows pEC ₅₀ values of 6.53 and 5.92 at hV1a and hV2 receptors, respectively, and behaved as a weak antagonist at hOT receptors (pKB=6.31) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Cristiana Grifante, et al. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol. 2005 Nov;146(5):744-51.
- [2]. Ling Ling Cheng, et al. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA